This guidance contains a set of recommendations based on scientific evidence (where available) and consensus of expert opinion to prevent cross transmission of Carbapenemase-producing Enterobacteriaceae (CPEs) within acute healthcare settings in NHSScotland.
This toolkit has been adapted from Public Health England’s (PHE) “Acute trust toolkit for the early detection, management and control of carbapenemase-producing Enterobacteriaceae” and takes account of recent published UK guidance on multi-drug resistant organisms (MDROs) from the Healthcare Infection Society. It supersedes the Scottish Interim Guidance, “Non-prescribing control measures to prevent cross-transmission of carbapenemase-producing Enterobacteriaceae”, published in June 2013.
The development of the toolkit followed the joint Chief Medical Officer (CMO)/Chief Nursing Officer (CNO)/Chief Pharmaceutical Officer (CPO) letter published in June 2013 describing the emerging threat from CPE and the requirements for an acute hospital admission screening programme for CPE. In March 2017, the Chief Nursing Officer issued a new letter to reinforce the mandatory policy requirement for screening in NHS boards across Scotland.
The associated guidance on CPE in non-acute settings is also available.